X
    X
    X
    X

    Edwards Wildman Advises Mnemosyne Pharmaceuticals in Series A Financing

    News
    Mnemosyne Pharmaceuticals Inc. has closed an additional $6 million in Series A financing for its drug discovery efforts focused on the identification of new drug treatments for schizophrenia and other neuropsychiatric disorders. Edwards Wildman advised Mnemosyne in this deal, and the team was led by Chris Graham, co-chair of the firm's Business Law Department and co-partner-in-charge of Edwards Wildman's Providence office, and Andrew Capalbo, a Providence-based associate in the firm's Business Law Department. The new financing is from Atlas Venture, a Cambridge, Mass., early stage investment firm dedicated to financing disruptive innovation in life sciences and technology, and from Clal Biotechnology Industries, an Israeli life sciences company, following a milestone funding among the existing Series A investors, including Slater Technology Fund. The new funding brings the total Series A financing raised by Mnemosyne to $11.4 million.

    Explore Additional Topics

    Disclaimer

    Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.